Article Per Year (5 Year)
p-Index From 2021 - 2026
0.702
P-Index
This Author published in this journals
All Journal Jurnal Health Sains Cermin Dunia Kedokteran Cermin Dunia Kedokteran
Maria Cecilia Gritce Widjaja
RSUD Teluk Wondama, Wasior, Papua Barat, Indonesia
Dentistry Health Professions Medicine & Pharmacology Nursing Public Health Veterinary

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
Kombinasi Insulin Basal Dengan GLP-1 RA Dalam FRC (IGLARLIXI) Terhadap Pencapaian Target DM Tipe 2 Maria Cecilia Gritce Widjaja
Jurnal Health Sains Vol. 3 No. 3 (2022): Jurnal Health Sains
Publisher : Syntax Corporation Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.46799/jhs.v3i3.440

Abstract

Management of diabetes melitus in Indonesia still needs to be improved, the presence of inertia at the time of initiation and intensification of insulin makes the HbA1c target not achieved (<7%). The use of basal insulin often does’nt give satisfactory results, seen from providing HbA1c, the risk of hypoglycemia, and weight gain. The purpose of this literature is to discuss the combination of basal insulin with GLP-1RA (iGlarLixi). Methods The writing of this literature uses a narrative review. Based on a review that has been reviewed, the use of iGlarLixi is superior to insulin alone in the treatment of DM. iGlarLixi provides HbA1c targets <7% more achieved, the risk of hypoglycemia that often occurs with basal insulin use, weight gain also didn’t occur and conversely iGlarLixi can provide a weight loss effect. iGlarLixi can be the first choice in patients with type 2 diabetes who are not controlled with insulin
Rejimen KDT-ARV terbaru dengan Dolutegravir Maria Cecilia Gritce Widjaja
Cermin Dunia Kedokteran Vol 49, No 6 (2022): Nutrisi
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v49i6.1879

Abstract

Terapi HIV/AIDS terus mengalami perkembangan. Rejimen ARV terbaru saat ini menggunakan Dolutegravir dalam rejimen KDT-ARV berupa KDT-TLD, yang berisi 2NRTI + INSTI. Rejimen baru ini diteliti mampu menekan jumlah virus lebih cepat, mengurangi efek neuropsikiatri dan mengurangi resistensi pada rejimen sebelumnya yang menggunakan efavirenz. Inisiasi ARV juga disarankan sedini mungkin (jika belum ada infeksi oportunistik) supaya dapat meningkatkan harapan hidup, menurunkan insiden infeksi oportunistik, dan mencegah transmisi virus HIV.HIV/AIDS therapy continues to develop over time. The current ARV regiment uses dolutegravir in ARV-FDC regiment in the form of a TLD-FDC containing 2NRTI + INSTI. This new regiment was intended to suppress viral load more rapidly, reduce neuropsychiatric effects and reduce resistance to previous regiments using efavirenz. ARV initiation is also recommended as early as possible (if there is no opportunistic infection) to increase life expectancy, reduce the incidence of opportunistic infections, and prevent transmission of HIV.
Rejimen KDT-ARV Terbaru dengan Dolutegravir Maria Cecilia Gritce Widjaja
Cermin Dunia Kedokteran Vol 49 No 6 (2022): Nutrisi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v49i6.239

Abstract

Terapi HIV/AIDS terus mengalami perkembangan. Rejimen ARV terbaru saat ini menggunakan dolutegravir dalam rejimen KDT-ARV berupa KDT-TLD, yang berisi 2NRTI + INSTI. Rejimen baru ini diteliti mampu menekan jumlah virus lebih cepat, mengurangi efek neuropsikiatri, dan mengurangi resistensi pada rejimen sebelumnya yang menggunakan efavirenz. Inisiasi ARV juga disarankan sedini mungkin (jika belum ada infeksi oportunistik), agar dapat meningkatkan harapan hidup, menurunkan insiden infeksi oportunistik, dan mencegah transmisi virus HIV. HIV/AIDS therapy continues to develop over time. The current ARV regiment uses dolutegravir in ARV-FDC regiment in the form of a TLD-FDC containing 2NRTI + INSTI. This new regiment was intended to suppress viral load more rapidly, reduce neuropsychiatric effects and reduce resistance to previous regiments using efavirenz. ARV initiation is also recommended as early as possible (if there is no opportunistic infection) to increase life expectancy, reduce the incidence of opportunistic infections, and prevent transmission of HIV.
Rejimen KDT-ARV Terbaru dengan Dolutegravir Maria Cecilia Gritce Widjaja
Cermin Dunia Kedokteran Vol 49 No 6 (2022): Nutrisi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v49i6.239

Abstract

Terapi HIV/AIDS terus mengalami perkembangan. Rejimen ARV terbaru saat ini menggunakan dolutegravir dalam rejimen KDT-ARV berupa KDT-TLD, yang berisi 2NRTI + INSTI. Rejimen baru ini diteliti mampu menekan jumlah virus lebih cepat, mengurangi efek neuropsikiatri, dan mengurangi resistensi pada rejimen sebelumnya yang menggunakan efavirenz. Inisiasi ARV juga disarankan sedini mungkin (jika belum ada infeksi oportunistik), agar dapat meningkatkan harapan hidup, menurunkan insiden infeksi oportunistik, dan mencegah transmisi virus HIV. HIV/AIDS therapy continues to develop over time. The current ARV regiment uses dolutegravir in ARV-FDC regiment in the form of a TLD-FDC containing 2NRTI + INSTI. This new regiment was intended to suppress viral load more rapidly, reduce neuropsychiatric effects and reduce resistance to previous regiments using efavirenz. ARV initiation is also recommended as early as possible (if there is no opportunistic infection) to increase life expectancy, reduce the incidence of opportunistic infections, and prevent transmission of HIV.
Co-Authors